FDA Approves DILTIAZEM HYDROCHLORIDE — Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories, LLC has received approval for its Abbreviated New Drug Application (ANDA) 205231 to manufacture generic DILTIAZEM HYDROCHLORIDE, a move likely to trigger price erosion in the cardiovascular market. Launch of this generic version is expected to expand access to the therapeutic for hypertension and angina.